Amryt Pharma plc

Amryt Pharma is a biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients diagnosed with rare or orphan diseases.

Amryt comprises a growing commercial business and a significant development pipeline. Their aim is to forge partnerships and collaborations that work for all. By interacting with stakeholders, they create a clear path for transformative medicines to reach those that need them.

In 2016, Raglan established Amryt Pharma Plc which is listed on both the London and Euronext exchanges. In 2020 Amryt, listed on the NASDAQ following the acquisition of Aegerion Pharmaceuticals in September 2019. Amryt is now an established European and North America orphan drug company and, in June 2020, it had a market capitalisation in excess of £281m.

Amryt’s lead drug candidate, FILSUVEZ® (formerly named AP101), is a potential treatment for Epidermolysis Bullosa (“EB”), a rare and distressing genetic skin disorder for which there is currently no treatment. The European and US market opportunity for EB is estimated to be in excess of €1.3 billion.

Amryt’s earlier stage product AP102 is focused on developing novel, next-generation somatostatin analogue (“SSA”) peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need, including acromegaly and Cushing’s disease.

In addition, Amryt holds an exclusive licence to sell Lojuxta (lomitapide) across Europe, the Middle East, Northern Africa, Turkey, Israel and the Commonwealth of Independent States. Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder, Homozygous Familial Hypercholesterolaemia (“HoFH”). This disorder impairs the body’s ability to remove low-density lipoprotein cholesterol from the blood.

In March 2018, Amryt in-licensed a pre-clinical gene-therapy platform technology, AP103, which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders.

For more information on Amryt, please visit